Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Adult
Aged
Aged, 80 and over
Antibodies
/ immunology
B7-H1 Antigen
/ antagonists & inhibitors
Bile Duct Neoplasms
/ drug therapy
Bile Ducts, Intrahepatic
/ immunology
Cohort Studies
Female
Humans
Immunohistochemistry
/ methods
Klatskin Tumor
/ drug therapy
Male
Middle Aged
Neoplasm Staging
Staining and Labeling
/ methods
Survival Analysis
Tissue Array Analysis
28–8
CD274
Cholangiocarcinoma
PD-L1
SP142
SP263
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
15 Jan 2019
15 Jan 2019
Historique:
received:
13
06
2018
accepted:
26
12
2018
entrez:
17
1
2019
pubmed:
17
1
2019
medline:
30
4
2019
Statut:
epublish
Résumé
Cholangiocarcinoma (CCA) may arise in the intra- or extrahepatic biliary tract and is associated with a poor prognosis. Despite recent advances, to date there is still no established targeted therapeutic approach available. Non-surgical therapeutic agents are urgently needed, as most patients are non-eligible to surgical resection. Anti-PD-L1 therapy prevents cancer cells from evading the immune system and has emerged as a new treatment option in several cancer entities. Recently, PD-L1 expression has been analyzed in comparably small CCA patient cohorts. However, a systematic validation of different PD-L1 antibodies has not been performed in CCA so far. We stained a tissue microarray consisting of 170 patients, including 72 intrahepatic cholangiocarcinomas (iCCAs), 57 perihilar cholangiocarcinomas (pCCAs) and 41 distal cholangiocarcinomas (dCCAs) by immunohistochemistry and evaluated PD-L1 positivity in tumor and stromal cells. We analyzed three different PD-L1 antibodies (clones 28-8, SP142, and SP263) that are frequently used and recommended for predictive diagnostic testing in other cancer types. For PD-L1 antibody clone SP263, 5% of iCCAs, 4% of pCCAs and 3% of dCCAs exhibited PD-L1 expression on tumor cells, thereby showing the highest frequencies of PD-L1 positivity. Accordingly, highest PD-L1 positivity rates of stromal cells with 31% in iCCA, 40% in pCCA and 61% in dCCA were detected for clone SP263. Agreement of PD-L1 positivity in tumor cells was moderate for clone 28-8 and SP263 (κ = 0.44) and poor between 28-8 and SP142 (κ = 0.13), as well as SP142 and SP263 (κ = 0.11), respectively. Statistical analyses of PD-L1 expression (clone SP263) on tumor cells with clinicopathological data revealed a positive correlation with shortened overall survival in CCA patients. Selection of appropriate PD-L1 antibodies and careful evaluation of immunohistochemical staining patterns have a significant impact on PD-L1 testing in CCA. Clinical trials are necessary to investigate the putative beneficial effects of PD-L1 targeted immunotherapy in CCA patients.
Sections du résumé
BACKGROUND
BACKGROUND
Cholangiocarcinoma (CCA) may arise in the intra- or extrahepatic biliary tract and is associated with a poor prognosis. Despite recent advances, to date there is still no established targeted therapeutic approach available. Non-surgical therapeutic agents are urgently needed, as most patients are non-eligible to surgical resection. Anti-PD-L1 therapy prevents cancer cells from evading the immune system and has emerged as a new treatment option in several cancer entities. Recently, PD-L1 expression has been analyzed in comparably small CCA patient cohorts. However, a systematic validation of different PD-L1 antibodies has not been performed in CCA so far.
METHODS
METHODS
We stained a tissue microarray consisting of 170 patients, including 72 intrahepatic cholangiocarcinomas (iCCAs), 57 perihilar cholangiocarcinomas (pCCAs) and 41 distal cholangiocarcinomas (dCCAs) by immunohistochemistry and evaluated PD-L1 positivity in tumor and stromal cells. We analyzed three different PD-L1 antibodies (clones 28-8, SP142, and SP263) that are frequently used and recommended for predictive diagnostic testing in other cancer types.
RESULTS
RESULTS
For PD-L1 antibody clone SP263, 5% of iCCAs, 4% of pCCAs and 3% of dCCAs exhibited PD-L1 expression on tumor cells, thereby showing the highest frequencies of PD-L1 positivity. Accordingly, highest PD-L1 positivity rates of stromal cells with 31% in iCCA, 40% in pCCA and 61% in dCCA were detected for clone SP263. Agreement of PD-L1 positivity in tumor cells was moderate for clone 28-8 and SP263 (κ = 0.44) and poor between 28-8 and SP142 (κ = 0.13), as well as SP142 and SP263 (κ = 0.11), respectively. Statistical analyses of PD-L1 expression (clone SP263) on tumor cells with clinicopathological data revealed a positive correlation with shortened overall survival in CCA patients.
CONCLUSIONS
CONCLUSIONS
Selection of appropriate PD-L1 antibodies and careful evaluation of immunohistochemical staining patterns have a significant impact on PD-L1 testing in CCA. Clinical trials are necessary to investigate the putative beneficial effects of PD-L1 targeted immunotherapy in CCA patients.
Identifiants
pubmed: 30646854
doi: 10.1186/s12885-018-5254-0
pii: 10.1186/s12885-018-5254-0
pmc: PMC6332835
doi:
Substances chimiques
Antibodies
0
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
72Références
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Clin Cancer Res. 2013 Mar 1;19(5):1021-34
pubmed: 23460533
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Nat Genet. 2015 Sep;47(9):967-8
pubmed: 26313225
Clin Cancer Res. 2016 Jan 15;22(2):470-8
pubmed: 26373575
Lancet. 2016 Apr 9;387(10027):1540-50
pubmed: 26712084
Crit Rev Oncol Hematol. 2016 Apr;100:88-98
pubmed: 26895815
Ann Surg Oncol. 2016 Aug;23(8):2610-7
pubmed: 27012989
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
J Hematol Oncol. 2016 May 27;9(1):47
pubmed: 27234522
Expert Rev Clin Immunol. 2017 Jan;13(1):77-84
pubmed: 27426025
J Urol. 2017 Jan;197(1):14-22
pubmed: 27460757
Int J Biol Markers. 2017 Mar 2;32(1):e68-e74
pubmed: 27470134
J Thorac Oncol. 2016 Nov;11(11):1927-1939
pubmed: 27496650
Pathologe. 2016 Nov;37(6):557-567
pubmed: 27510417
Oncotarget. 2016 Nov 8;7(45):74350-74361
pubmed: 27542277
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Eur J Surg Oncol. 2017 Mar;43(3):604-611
pubmed: 27769635
J Clin Oncol. 2016 Dec;34(34):4102-4109
pubmed: 27863197
J Thorac Oncol. 2017 Feb;12(2):208-222
pubmed: 27913228
Pathol Int. 2017 Mar;67(3):163-170
pubmed: 28139862
Ann Pathol. 2017 Feb;37(1):39-45
pubmed: 28159404
J Hepatol. 2017 Sep;67(3):632-644
pubmed: 28389139
Histopathology. 2017 Sep;71(3):383-392
pubmed: 28419539
Oncotarget. 2017 Apr 11;8(15):24644-24651
pubmed: 28445951
Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5):null
pubmed: 28619747
Asian Pac J Cancer Prev. ;18(6):1671-1674
pubmed: 28670887
Oncol Lett. 2017 Jul;14(1):250-256
pubmed: 28693161